Neuroxelin is a research-blend name, not a single naturally occurring brain hormone. This guide examines the four-ingredient formulation described as PE-22-28, Pinealon, N-acetyl Semax and N-acetyl Selank. A current manufacturer specification for that formulation could not be independently confirmed for this review. Do not assume that every product using the name has those exact forms or amounts.
The component studies below investigate individual ingredients, not the finished combination. They don’t verify the contents or effectiveness of a product sold as Neuroxelin.
Related dosage pages: For vial-specific concentration, reconstitution, and measurement examples, see Neuroxelin (48 mg Vial) Dosage Protocol. Each linked protocol remains a separate reference because vial strength changes concentration and syringe-unit calculations.
Published studies on individual components help explain the interest in this blend. They do not show that the combination improves memory, treats anxiety or protects the human brain. In the literature search for this guide, we did not identify a published human trial of the exact Neuroxelin blend.
What is in Neuroxelin?
The four names point to different lines of research. Some concern ion channels, some cellular stress, and others signaling associated with learning or anxiety. Calling them all “brain peptides” can obscure those differences.
| Ingredient name | Research context |
|---|---|
| PE-22-28 | A shortened spadin-related peptide studied for TREK-1 potassium-channel inhibition and effects in mouse behavioral models. It is not a clinically established antidepressant. [1] |
| Pinealon | A three-amino-acid peptide, also called Glu-Asp-Arg or EDR. A rat study examined cognitive and neuronal effects after prenatal exposure to high homocysteine. [2] |
| N-acetyl Semax | A modified form whose name must be distinguished from Semax. The frequently cited BDNF study used Semax in rats, not this four-part blend. [3] |
| N-acetyl Selank | A modified form that should not be treated as equivalent to Selank. A small human anxiety study investigated Selank, not N-acetyl Selank in Neuroxelin. [4] |
A total vial amount, such as 48 mg, is not an amount for each ingredient and is not a dose recommendation. Exact component amounts and chemical forms need to come from the current product specification. A blend name alone is not enough to verify them.
What does the research show?
PE-22-28: cells and mice, not a human depression trial
A 2017 study examined shortened spadin analogs in cell experiments and mouse models. PE-22-28 inhibited TREK-1, an ion channel involved in neuronal activity, and changed outcomes in behavioral tests used in antidepressant research. [1]
That makes it a research lead. A mouse behavioral test is not a diagnosis of human depression, and a change in that test is not proof that a person will feel better. The study also investigated several modified analogs, so results for one should not automatically be assigned to another.
Pinealon: a specific developmental-stress model
In a 2012 experiment, researchers studied offspring of rats exposed to excess methionine during pregnancy, producing high homocysteine levels. Pinealon was associated with better performance on learning measures and greater resistance of neurons to oxidative stress. [2]
This is much more specific than “supports memory.” It does not establish improved focus in healthy adults, prevention of dementia, or effectiveness of an adult Neuroxelin regimen. The setting, species and outcome all limit the conclusion.
Semax: BDNF is a biological marker, not a promised benefit
A rat study reported changes in brain-derived neurotrophic factor, or BDNF, and its TrkB receptor after intranasal Semax. It also examined a learned behavioral response. [3]
BDNF is relevant to brain signaling, which is why the result attracts attention. But a change in a rat’s brain tissue cannot be translated into a guaranteed improvement in a person’s memory or concentration. The study did not test N-acetyl Semax as part of Neuroxelin.
Selank: some human research, with important limits
A 2008 study included 62 people with generalized anxiety disorder or neurasthenia. Thirty received Selank and 32 received medazepam. The authors reported similar effects on anxiety measures. [4]
This is human evidence, not just an animal experiment. Still, the available abstract does not provide enough detail to establish the size or durability of the benefit, and it does not answer long-term safety questions. Most importantly for this article, it studied Selank, not the N-acetyl derivative or the combined blend.
Quick check: do four promising ingredients prove that the blend works?
No. Each ingredient’s evidence belongs to its tested form, route and population. To demonstrate a benefit from the combination, the combination itself needs appropriate testing. An appealing explanation of how the ingredients might complement one another is a hypothesis, not proof of synergy.
Why the N-acetyl wording matters
Small changes to a peptide’s chemical structure can matter. Do not quietly drop “N-acetyl” when matching a product label to a paper, or assume the modification makes the compound stronger, longer-lasting or safer in humans.
There is another easy naming trap: Selank acetate is not the same naming statement as N-acetyl Selank. An acetate salt and an N-acetyl chemical modification should not be treated as interchangeable. If the exact form is unclear, that uncertainty belongs in the interpretation, not hidden in a footnote.
For the same reason, a study of a nasal preparation does not automatically support injection of a blend. A different route changes the question being asked. The label, formulation and study methods need to match before making a direct comparison.
Neuroxelin safety and side effects
There is no reliable side-effect rate for this exact blend in the evidence reviewed here. That means “unknown,” not “no side effects.” The same gap applies to interactions, long-term use and effects in pregnancy or in people with significant medical conditions.
The FDA identifies potential immune-response and peptide-impurity concerns for compounded Semax and Selank acetate, and notes important missing safety information. Those notices concern the named substances and do not quantify the risks of N-acetyl derivatives or Neuroxelin. They are a reason for caution, not a substitute for blend-specific data. [5]
A research-use label, a purity number and a plausible mechanism answer different questions. None establishes that a product is a suitable treatment for anxiety, brain fog, memory loss or a neurological condition.
If memory or concentration is the real concern
Persistent changes deserve assessment rather than a guess about which peptide is missing. Memory problems can be associated with medication effects, depression, thyroid problems and other conditions, as well as neurological disease. A healthcare professional can help distinguish these possibilities. [6]
Bring a list of medicines and supplements, when the symptoms began, and examples of how they affect daily life. Those details are more useful to a clinician than a general aim to “optimize brain health.” Do not stop prescribed treatment or replace it with a research blend.
How to judge a Neuroxelin claim
A short checklist makes dense research easier to interpret:
- Match the substance. Is the paper about the exact blend, an individual ingredient or a different derivative?
- Match the population. Cells, mice, healthy adults and people with a diagnosed illness are not equivalent.
- Read the outcome. A marker such as BDNF is not the same as improved everyday memory.
- Check the comparison. Was there a control group, and were important differences actually measured?
- Keep the missing information visible. An unknown interaction or side-effect rate cannot be filled in with testimonials.
For example, a claim that a blend “builds new brain connections in four days” might be linked to a short mouse experiment on a single peptide. The citation can be real while the conclusion is still too broad. Reading the methods is what exposes the gap.
Common questions
Is Neuroxelin the same as Semax plus Selank?
No. The blend discussed here also names PE-22-28 and Pinealon, and it specifies N-acetyl versions of Semax and Selank. A study of the unmodified pair would still not be a study of that four-ingredient formulation.
Is it a proven nootropic?
“Nootropic” is a broad label used in discussions of cognition. It is not a level of evidence. The component studies are interesting, but this guide did not identify a human trial demonstrating cognitive benefit from the exact Neuroxelin blend.
Can the component studies establish a dose or cycle?
No. Combining amounts from separate animal or human experiments would create a new, untested regimen. A concentration calculation can describe what is in a solution; it cannot establish a clinically appropriate dose.
Is Neuroxelin the same as a similarly named brain supplement?
No. Similar spelling does not establish similar ingredients. Check the complete ingredient list rather than assuming that reviews of a capsule or vitamin product apply to this peptide blend.
Bottom line: Neuroxelin brings several research ideas into one blend name, but the evidence still needs to be read ingredient by ingredient. There is a substantial gap between early findings and a demonstrated human benefit from the finished combination. Discuss cognitive or mental-health symptoms with a qualified healthcare professional.
References
- Djillani et al. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. 2017.
- Arutjunyan et al. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. 2012.
- Dolotov et al. Semax regulates BDNF and TrkB expression in the rat hippocampus. 2006.
- Zozulia et al. Selank in generalized anxiety disorders and neurasthenia. 2008. Russian-language study; English abstract.
- U.S. FDA. Bulk drug substances that may present significant safety risks.
- MedlinePlus. Memory and when to seek assessment.
Related dosage protocols and research
Explore related research, dosage references and guides below. Vial strengths have separate references because concentration and syringe-unit calculations differ. A comparison does not mean the compounds are interchangeable. The N-acetyl Semax and N-acetyl Selank components in Neuroxelin are modified forms; the standalone Semax and Selank protocols are linked only for comparison.
Matching dosage protocols
Related protocols and comparisons
Further research context